Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 112 clinical trials
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (TACE-SBRT)

radiation as consolidation therapy after TACE in patients with nonmetastatic unresectable HCC.

sorafenib
unresectable hepatocellular carcinoma
TACE
systemic chemotherapy
cancer
  • 42 views
  • 11 May, 2022
  • 2 locations
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma

pomalidomide maintenance therapy 3 months after ASCT; 2) patients not suitable for ASCT started pomalidomide maintenance therapy after induction and consolidation therapy to achieve maximum efficacy. Dosing on

  • 0 views
  • 23 Jul, 2022
  • 1 location
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

. Using a standard 3+3 design, subjects will receive once cycle of combination therapy. After one cycle of combination therapy, subjects showing response will continue on to one cycle of consolidation

azacitidine
gemtuzumab
cancer
blast cells
venetoclax
  • 16 views
  • 22 Jul, 2022
  • 4 locations
Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Introduction: Although PACIFIC regimen definitive concurrent chemoradiotherapy (CRT) followed by Durvalumab consolidation therapy is considered the standard of care for most of stage III NSCLC

  • 0 views
  • 26 Dec, 2021
  • 1 location
Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Single center, open-label, phase 2 study to determine the efficacy of cirmtuzumab consolidation in patients with measurable disease on venetoclax.

chronic lymphocytic leukemia
venetoclax
measurable disease
  • 0 views
  • 08 Dec, 2021
  • 1 location
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.

  • 0 views
  • 08 Sep, 2021
  • 1 location
Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

20 mg or 40 mg of quizartinib will be given to Chinese patients who were just diagnosed with AML. The study drug will be given to them along with standard therapies. The purpose is to find out the highest dose they can stand.

cytarabine
  • 8 views
  • 25 Apr, 2022
  • 1 location
Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

This study was a prospective, multi-center, single-arm, Phase II clinical study. Compared with the literature data, objective response rate (ORR) and complete response rate (CR) were the primary endpoint, and 1-year and 2-year progression-free survival (PFS) and 2-year overall survival (OS) were the secondary endpoint. To evaluate the efficacy and …

  • 0 views
  • 30 Sep, 2021
  • 1 location
Donor Immune Cell Therapy for Acute Myeloid Leukemia

This study aims to introduce a new technology of donor NK cell infusion. NK cells defend against viruses and cancer cells in vivo whereas this effect declines in patiens with tumors. In this study, NK cells will be separated from donated peripheral blood or umbilical cord blood. Eligible NK cells …

  • 0 views
  • 28 Apr, 2022
  • 1 location
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.

avid
eflornithine
cancer
etoposide
bone marrow procedure
  • 0 views
  • 13 May, 2022
  • 19 locations